Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Scientific advisers
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
    • Patients
    • Expanded access policy
  • Research & Development
    • Projects
      • KL1333
      • NV354
      • Early programs
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • Capital Markets Day 2020
      • Mitochondria Day 2020
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

IR contact

Abliva AB intends to provide the financial markets with accurate, consistent and relevant information on the company on a regular basis. In the first instance, IR-related issues should be addressed to the IR Director.

Catharina Johansson, CFO & Vice President Investor Relations
E-mail: ir@abliva.com
Tel: +46 [0] 46-275 62 21

Investor relations

Share and owner information

Abliva AB is listed on Nasdaq Stockholm and trades under the ticker ABLI. Nasdaq The share capital is SEK 14,817,006.60 divided between 296,340,132 shares of only one class. All shares have a quotient value of SEK 0.05 and confer entitlement to one vote and equal participation in the company’s assets and earnings. Insider trading (Finansinspektionen/The Swedish Securities and Exchange Commission) Major […]

Interim reports

Here you'll find all Abliva's interim reports.

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage
  2. Investors
  3. IR contact

This is Abliva

  • Strategy
  • Orphan Drugs
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • BD Contact
  • Partnering

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
Scheelevägen 2
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookies policy | Privacy policy | Terms and Conditions

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all